


**Product Name** : JNJ-38877618  
**Cat. No.** : PC-63402  
**CAS No.** : 943540-74-7  
**Molecular Formula** : C<sub>20</sub>H<sub>12</sub>F<sub>2</sub>N<sub>6</sub>  
**Molecular Weight** : 374.355  
**Target** : c-Met (HGFR)  
**Solubility** :



### Biological Activity

JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable **c-Met tyrosine kinase** inhibitor with K<sub>d</sub> of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively; potently inhibits MET receptor phosphorylation and downstream pathway modulation in the nanomolar range and induces anti-proliferative and anti-migratory activity in models with MET gene amplification, mutant or ligand-mediated pathway activation; completely suppresses tumour growth SNU5 MET amplified gastric, U87-MG HGF autocrine glioblastoma and Hs746T MET exon 14 skipping mutant gastric cancer models.

Solid Tumors  
Phase 1 Clinical

### References

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com